Literature DB >> 23792571

Amyloid precursor-like protein 2 suppresses irradiation-induced apoptosis in Ewing sarcoma cells and is elevated in immune-evasive Ewing sarcoma cells.

Haley L Peters1, Ying Yan, Tara M Nordgren, Christine E Cutucache, Shantaram S Joshi, Joyce C Solheim.   

Abstract

Despite surgery, chemotherapy, and radiotherapy treatments, the children, adolescents, and young adults who are diagnosed with metastasized Ewing sarcoma face a dismal prognosis. Amyloid precursor-like protein 2 (APLP2) has recently been implicated in the survival of cancer cells and in our current study, APLP2's contribution to the survival of Ewing sarcoma cells was examined. APLP2 was readily detected in all Ewing sarcoma cell lines analyzed by western blotting, with the TC71 Ewing sarcoma cells expressing the lowest level of APLP2 among the lines. While irradiation induces apoptosis in TC71 Ewing sarcoma cells (as we determined by quantifying the proportion of cells in the sub-G 1 population), transfection of additional APLP2 into TC71 decreased irradiation-induced apoptosis. Consistent with these findings, in parallel studies, we noted that isolates of the TC71 cell line that survived co-culture with lymphokine-activated killer (LAK) cells (which kill by inducing apoptosis in target cells) displayed increased expression of APLP2, in addition to smaller sub-G 1 cell populations after irradiation. Together, these findings suggest that APLP2 lowers the sensitivity of Ewing sarcoma cells to radiotherapy-induced apoptosis and that APLP2 expression is increased in Ewing sarcoma cells able to survive exposure to cytotoxic immune cells.

Entities:  

Keywords:  Ewing sarcoma; amyloid precursor-like protein 2; cytotoxic; immune evasion; immunotherapy; lymphokine-activated killer cell; radiation

Mesh:

Substances:

Year:  2013        PMID: 23792571      PMCID: PMC3841215          DOI: 10.4161/cbt.25183

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  51 in total

1.  Fe65 is required for Tip60-directed histone H4 acetylation at DNA strand breaks.

Authors:  Maria Stante; Giuseppina Minopoli; Fabiana Passaro; Maddalena Raia; Luigi Del Vecchio; Tommaso Russo
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-12       Impact factor: 11.205

Review 2.  How do cytotoxic lymphocytes kill their targets?

Authors:  S Shresta; C T Pham; D A Thomas; T A Graubert; T J Ley
Journal:  Curr Opin Immunol       Date:  1998-10       Impact factor: 7.486

3.  Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC).

Authors:  Pierpaolo Correale; Monica Marra; Cinzia Remondo; Cristina Migali; Gabriella Misso; Felice Paolo Arcuri; Maria Teresa Del Vecchio; Antonietta Carducci; Lucia Loiacono; Pierfrancesco Tassone; Alberto Abbruzzese; Pierosandro Tagliaferri; Michele Caraglia
Journal:  Eur J Cancer       Date:  2010-06       Impact factor: 9.162

4.  Cytotoxicity of activated natural killer cells against pediatric solid tumors.

Authors:  Duck Cho; David R Shook; Noriko Shimasaki; Yu-Hsiang Chang; Hiroyuki Fujisaki; Dario Campana
Journal:  Clin Cancer Res       Date:  2010-06-11       Impact factor: 12.531

5.  Phenotypic and functional analysis of human CD3+ and CD3- clones with "lymphokine-activated killer" (LAK) activity. Frequent occurrence of CD3+ LAK clones which produce interleukin-2.

Authors:  M C Mingari; S Ferrini; D Pende; C Bottino; I Prigione; A Moretta; L Moretta
Journal:  Int J Cancer       Date:  1987-10-15       Impact factor: 7.396

6.  Radiation recall myositis in pediatric Ewing sarcoma.

Authors:  Jona Hattangadi; Brittany Esty; Brian Winey; Shauna Duigenan; Mary Huang; Torunn Yock
Journal:  Pediatr Blood Cancer       Date:  2011-10-20       Impact factor: 3.167

7.  Natural killer (NK) cells as a responder to interleukin 2 (IL 2). II. IL 2-induced interferon gamma production.

Authors:  K Handa; R Suzuki; H Matsui; Y Shimizu; K Kumagai
Journal:  J Immunol       Date:  1983-02       Impact factor: 5.422

8.  Tumor targets stimulate IL-2 activated killer cells to produce interferon-gamma and tumor necrosis factor.

Authors:  A S Chong; P Scuderi; W J Grimes; E M Hersh
Journal:  J Immunol       Date:  1989-03-15       Impact factor: 5.422

9.  Amyloid precursor-like protein 2 increases the endocytosis, instability, and turnover of the H2-K(d) MHC class I molecule.

Authors:  Amit Tuli; Mahak Sharma; Mary M McIlhaney; James E Talmadge; Naava Naslavsky; Steve Caplan; Joyce C Solheim
Journal:  J Immunol       Date:  2008-08-01       Impact factor: 5.422

10.  Inhibition of melanoma tumor growth in vivo by survivin targeting.

Authors:  D Grossman; P J Kim; J S Schechner; D C Altieri
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-09       Impact factor: 11.205

View more
  10 in total

1.  Beta 2-microglobulin regulates amyloid precursor-like protein 2 expression and the migration of pancreatic cancer cells.

Authors:  Bailee H Sliker; Benjamin T Goetz; Haley L Peters; Brittany J Poelaert; Gloria E O Borgstahl; Joyce C Solheim
Journal:  Cancer Biol Ther       Date:  2019-02-27       Impact factor: 4.742

2.  EWS/FLI is a Master Regulator of Metabolic Reprogramming in Ewing Sarcoma.

Authors:  Jason M Tanner; Claire Bensard; Peng Wei; Nathan M Krah; John C Schell; Jamie Gardiner; Joshua Schiffman; Stephen L Lessnick; Jared Rutter
Journal:  Mol Cancer Res       Date:  2017-07-18       Impact factor: 5.852

3.  APLP2 regulates the expression of MHC class I molecules on irradiated Ewing's sarcoma cells.

Authors:  Haley L Peters; Ying Yan; Joyce C Solheim
Journal:  Oncoimmunology       Date:  2013-10-08       Impact factor: 8.110

Review 4.  A review of soft-tissue sarcomas: translation of biological advances into treatment measures.

Authors:  Ngoc T Hoang; Luis A Acevedo; Michael J Mann; Bhairavi Tolani
Journal:  Cancer Manag Res       Date:  2018-05-10       Impact factor: 3.989

5.  Amyloid Precursor-like Protein 2 Expression Increases during Pancreatic Cancer Development and Shortens the Survival of a Spontaneous Mouse Model of Pancreatic Cancer.

Authors:  Brittany J Poelaert; Shelby M Knoche; Alaina C Larson; Poomy Pandey; Parthasarathy Seshacharyulu; Nuzhat Khan; H Carlo Maurer; Kenneth P Olive; Yuri Sheinin; Rizwan Ahmad; Amar B Singh; Surinder K Batra; Satyanarayana Rachagani; Joyce C Solheim
Journal:  Cancers (Basel)       Date:  2021-03-26       Impact factor: 6.639

Review 6.  Transcription addiction: can we garner the Yin and Yang functions of E2F1 for cancer therapy?

Authors:  P Meng; R Ghosh
Journal:  Cell Death Dis       Date:  2014-08-07       Impact factor: 8.469

7.  Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma.

Authors:  Maurizio Ghisoli; Minal Barve; Reva Schneider; Robert Mennel; Carl Lenarsky; Gladice Wallraven; Beena O Pappen; John LaNoue; Padmasini Kumar; Derek Nemunaitis; Alyssa Roth; James Nemunaitis; Sam Whiting; Neil Senzer; Frederick A Fletcher; John Nemunaitis
Journal:  Mol Ther       Date:  2015-03-19       Impact factor: 11.454

Review 8.  Amyloid precursor protein and amyloid precursor-like protein 2 in cancer.

Authors:  Poomy Pandey; Bailee Sliker; Haley L Peters; Amit Tuli; Jonathan Herskovitz; Kaitlin Smits; Abhilasha Purohit; Rakesh K Singh; Jixin Dong; Surinder K Batra; Donald W Coulter; Joyce C Solheim
Journal:  Oncotarget       Date:  2016-04-12

Review 9.  Oncofetal Chondroitin Sulfate: A Putative Therapeutic Target in Adult and Pediatric Solid Tumors.

Authors:  Nastaran Khazamipour; Nader Al-Nakouzi; Htoo Zarni Oo; Maj Ørum-Madsen; Anne Steino; Poul H Sorensen; Mads Daugaard
Journal:  Cells       Date:  2020-03-28       Impact factor: 6.600

10.  Sex-dependent effects of amyloid precursor-like protein 2 in the SOD1-G37R transgenic mouse model of MND.

Authors:  Phan H Truong; Peter J Crouch; James B W Hilton; Catriona A McLean; Roberto Cappai; Giuseppe D Ciccotosto
Journal:  Cell Mol Life Sci       Date:  2021-09-02       Impact factor: 9.261

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.